Salvatore Mannino, DO
Interventional Cardiology · Marietta, GANPI 1952363202
Payments from drug & device makers
Across 442 payments — averaging $1514.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$295K
- Abiomed$168K
- Shockwave Medical, Inc$142K
- Abbott$31K
- Boston Scientific$15K
- Siemens Medical Solutions USA, Inc.$12K
- plus $5K from 28 others
Across 1 payment — averaging $500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$500
What the payments were for
- Consulting fees$22,8658%
- Speaking & faculty fees$173,59863%
- Travel & lodging$64,89824%
- Food & beverage$13,3375%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 53 | $295,354 |
| Abiomed | 136 | $168,370 |
| Shockwave Medical, Inc | 68 | $141,756 |
| Abbott | 37 | $31,127 |
| Boston Scientific | 33 | $14,966 |
| Siemens Medical Solutions USA, Inc. | 30 | $12,169 |
| Philips North America LLC | 6 | $1,429 |
| Corindus Inc. | 7 | $1,309 |
| Angiodynamics, Inc. | 4 | $460 |
| Inari Medical, Inc. | 2 | $341 |
| Penumbra, Inc. | 2 | $296 |
| Novartis | 12 | $221 |
| Pfizer | 9 | $175 |
| Livanova USA, Inc. | 2 | $157 |
| W. L. Gore & Associates, Inc. | 1 | $145 |
| Procyrion, Inc. | 1 | $136 |
| AstraZeneca | 7 | $122 |
| Amgen | 7 | $113 |
| Teleflex LLC | 1 | $93 |
| Novo Nordisk | 3 | $54 |
| Merck | 3 | $53 |
| Johnson & Johnson | 3 | $52 |
| Recor Medical Inc | 2 | $51 |
| Edwards Lifesciences | 1 | $43 |
| Bayer | 2 | $41 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Amarin Pharma, Inc. | 2 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $22 |
| Lundbeck LLC | 1 | $20 |
| Boehringer Ingelheim | 1 | $17 |
| Cordis US CORP. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Terumo Medical Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$167,022
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$45,641
- COROFLOW$16,951
- Resolute$3,180
- CorPath Imaging System$2,565
- RESOLUTE ONYX$1,905
- CorPath GRX$1,809
- ONYX FRONTIER$1,467
- Ultreon$1,100
- (6574) Coronary Other$1,079
- FLOWTRIEVER CATHETER, S$341
- CT THROMBECTOMY SYSTEM KIT$341
- Vascular Lithotripsy$336
- AngioVac$318
- DRAGONFLY OPSTAR$299
- Indigo System$296
- GENERAL - STENTS$279
- OPTICROSS$265
- (9520) IGT Devices Undivided$188
- Rotablator Rotational Atherectomy System Console Kit$175
How this compares
$669,212 in reported general payments places this provider in the 90th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 272 | $315,384 |
| Repatha SureclickEvolocumab | 35 | $30,636 |
| BrilintaTicagrelor | 31 | $27,265 |
| Repatha SyringeEvolocumab | 11 | $7,197 |
| Ranolazine ErRanolazine | 70 | $5,986 |
| NexletolBempedoic Acid | 11 | $4,972 |
| Atorvastatin Calcium | 470 | $3,726 |
| ClopidogrelClopidogrel Bisulfate | 372 | $3,565 |
| Rosuvastatin Calcium | 272 | $3,117 |
| Metoprolol Succinate | 317 | $3,020 |
| Valsartan | 101 | $2,485 |
| Carvedilol | 341 | $2,418 |
| Potassium Chloride | 104 | $2,045 |
| Torsemide | 76 | $1,692 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 135 | $1,579 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $175 | $315,384272 claims |
| AstraZenecaBrilinta | $122 | $27,26531 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 218 interventional cardiology providers in Georgia.
Other interventional cardiology in Marietta
- Amar PatelMarietta$1.8M
- Paul GuichardMarietta$377K
- Arthur ReitmanMarietta$275K
- Ahmed Al BadriMarietta$110K
- David KandzariAtlanta$3.7M
- Pradeep YadavAtlanta$3.5M
- Vasilis BabaliarosAtlanta$2.7M
- Megan CoylewrightCalhoun$2.3M
- William NicholsonAtlanta$2M
- Chandanreddy DevireddyAtlanta$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.